A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma
| Autor: | Scott H, Okuno, Robert, Delaune, Jeff A, Sloan, Nathan R, Foster, Matthew J, Maurer, Marie-Christine, Aubry, Kendrith M, Rowland, Gamini S, Soori, Daniel A, Nikcevich, Carl G, Kardinal, Donald W, Northfelt, Alex A, Adjei, Anthony J, Jaslowski |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Adult
Male Mesothelioma Antimetabolites Antineoplastic Cancer Research medicine.medical_specialty Neutropenia Pleural Neoplasms medicine.medical_treatment Phases of clinical research Deoxycytidine Gastroenterology Internal medicine Antineoplastic Combined Chemotherapy Protocols Ribonucleotide Reductases Humans Medicine Aged Epirubicin Aged 80 and over Chemotherapy Antibiotics Antineoplastic business.industry Remission Induction Cancer Leukopenia Middle Aged medicine.disease Thrombocytopenia Gemcitabine Chemotherapy regimen Surgery Survival Rate Regimen Treatment Outcome Oncology Injections Intravenous Disease Progression Quality of Life Female business Follow-Up Studies medicine.drug |
| Zdroj: | Cancer. 112:1772-1779 |
| ISSN: | 1097-0142 0008-543X |
| DOI: | 10.1002/cncr.23313 |
| Popis: | BACKGROUND. The North Central Cancer Treatment Group (NCCTG) conducted a phase 2 study to evaluate the antitumor activity of the combination of gemcitabine and epirubicin in patients with pleural mesothelioma who received no more than 1 prior chemotherapy regimen. METHODS. A total of 23 patients were accrued between August 2001 and April 2002 and received gemcitabine at a dose of 1000 mg/m2 intravenously over 30 minutes weekly every 2 weeks and epirubicin at a dose of 90 mg/m2 intravenously on Day 1 on an every-21-days cycle (high-dose patient group). Between August 2002 and April 2004, an additional 45 patients were treated at a reduced dose of gemcitabine of 750 mg/m2 and epirubicin at a dose of 70 mg/m2 with the same schedule (low-dose patient group). RESULTS. In the high-dose patient group, the confirmed response rate was 13% (95% confidence interval [95% CI], 3–34%). The median survival was 9.3 months (95% CI, 7.4–10.7 months) and the median time to disease progression was 6.3 months (95% CI, 3.0–7.6 months). In the low-dose patient group, the confirmed response rate was 7% (95% CI, 0–28%). The median survival was 5.7 months (95% CI, 4.7–8.7 months) and the median time to disease progression was 4.2 months (95% CI, 2.7–5.6 months). Toxicity was moderate to severe. In the high-doseand low-dose groups, 87% and 60% of patients, respectively, experienced at least 1 adverse event of grade 4 or higher (according to National Cancer Institute Common Toxicity Criteria [version 2.0]). The quality of life remained similar from baseline to the end of the 2 cycles of treatment in the high-dose group but worsened in the low-dose group. CONCLUSIONS. In the current study, the combination regimen of gemcitabine and epirubicin was found to demonstrate minimal antitumor activity against pleural mesothelioma. Cancer 2008. © 2008 American Cancer Society. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text